Royal Marsden Hospital

What Royal Marsden Hospital does

The Royal Marsden NHS Foundation Trust, founded in 1851, is the world's first hospital dedicated to cancer diagnosis, treatment, research and education and operates as a public benefit corporation within the UK's National Health Service. The Trust runs two main hospital sites — Chelsea (London) and Sutton (Surrey) — supplemented by a Cavendish Square outpatient facility and a Medical Day Care Unit in partnership with Kingston Hospital, and is recognised among the world's top ten specialised hospitals (Newsweek 2026) with a CQC 'Outstanding' rating. It treats more than 60,000 patients per year, making it Europe's largest cancer centre, and runs the largest private cancer care practice in the UK.

Its clinical technology stack spans advanced radiotherapy (including CyberKnife and IMRT), molecular radiotherapy with personalised dosimetry, robotic microsurgery (first clinical use of MMI's Symani Surgical System with NanoWrist instruments and Synaptix Digital Surgery Platform), chemotherapy, surgery, and a clinical genomics service. Research infrastructure includes the NIHR Biomedical Research Centre, Oak Foundation Drug Development Unit, Ralph Lauren Centre for Breast Cancer Research, and West Wing Clinical Research Centre; education is delivered through The Royal Marsden School. Digitally, it operates the MyMarsden patient portal, Marsden360 second-opinion service, and MyTrack Myeloma remote monitoring service.

Revenue is generated through three primary streams: NHS-funded care (core public block funding for free-at-point-of-care treatment across all cancer types), Private Care (self-pay and insured patients across diagnostics, radiotherapy, surgery and second opinions, with published prices ranging from £354 to £16,235 per service), and charitable donations via The Royal Marsden Cancer Charity. GTM motion combines NHS referral pathways, a dedicated Business Relations Team driving GP-led private referrals, an International Patient Centre with multilingual coordinators (Arabic, Chinese, English) for overseas patients, and content-led engagement through RM Magazine, social channels, and the GP Education Series.

Name

Royal Marsden Hospital

Legal name

The Royal Marsden NHS Foundation Trust

Website

https://royalmarsden.nhs.uk

Company type

Private

Founded year

1851

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

The Royal Marsden NHS Foundation Trust, founded in 1851, is the world's first hospital dedicated to cancer diagnosis, treatment, research and education. It operates two UK hospital sites in Chelsea and Sutton plus international services, treating over 60,000 cancer patients annually through NHS funding, private care, and charitable support.

Ownership category

akta.pro rank

Product category

Specialty Cancer Hospital Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Offices of Physicians (62111), Ambulatory Health Care Services (621)

SIC

Services-Hospitals (8060), Services-Health Services (8000)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI), Medical Oncology (HLAKAFAB), Oncology Telemedicine Platforms (HLALAGAH), Specialty Palliative Care (e.g., oncology, CHF/COPD, dementia) (HLADAHAJ)

Keywords

• Cancer treatment services
• Oncology hospital care
• Cancer research and trials
• Radiotherapy and chemotherapy
• Specialist cancer diagnostics

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices4 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain, Others

Revenue model

1. NHS Funded Care: Core NHS services funded through government healthcare allocation. Provides free-at-point-of-care treatment to NHS patients across all cancer types.
2. Private Care: Private patient services including self-pay diagnostics and treatments, insured patient care, and international patient services. Estimated prices range from £354 (colorectal diagnostics) to £16,235 (10-fraction IMRT radiotherapy). Multiple revenue streams from consultations, diagnostics, treatments, and procedures.
3. Charitable Donations: The Royal Marsden Cancer Charity raises money solely to support The Royal Marsden, funding state-of-the-art equipment, groundbreaking research, and patient environment improvements.

Pricing tiers

Go-to-market motion2 records

Distribution channels6 records

Marketing channels8 records

Core offering

The Royal Marsden NHS Foundation Trust is a specialist cancer hospital providing comprehensive oncology services across the full patient pathway: diagnosis, treatment (radiotherapy, chemotherapy, surgery including robotic microsurgery), personalised medicine (molecular radiotherapy dosimetry, clinical genomics), palliative and supportive care, and clinical trials. It serves NHS-funded patients, self-paying and insured private UK patients, and international patients across two main hospital sites in Chelsea and Sutton, supplemented by satellite facilities at Cavendish Square and Kingston Hospital.

Product overview

The Royal Marsden is the world's first hospital dedicated to cancer diagnosis, treatment, research and education, operating as a NHS Foundation Trust with two main hospital sites in Chelsea, London and Sutton, Surrey. The hospital offers a comprehensive portfolio of cancer services including Genomics Service, Dosimetry Service, Marsden360 (expert second opinions), MyTrack Myeloma (remote patient monitoring), radiotherapy, chemotherapy, surgery, and clinical trials. Research capabilities include the NIHR Biomedical Research Centre, Oak Foundation Drug Development Unit, and Ralph Lauren Centre for Breast Cancer Research. Education is provided through The Royal Marsden School. Private Care services operate alongside NHS services, and patients can access care through the MyMarsden digital portal.

Differentiator

Problem solved

Functional benefit

Brands

• Royal Marsden Cancer Charity: Charity arm of The Royal Marsden that raises money solely to support the hospital through donations, events, and fundraising activities.
• MyMarsden
• Marsden360
• MyTrack Myeloma

Products and services

• Clinical Genomics Service Provides an extensive repertoire of genomic testing with cutting-edge technology, personalised to the patient, supporting both clinical and commercial partners in cancer diagnosis and treatment planning.
• Dosimetry Service Specialist radiation dosimetry and support services for molecular radiotherapy, delivered by a team of clinical and research scientists using leading-edge theragnostic image analytics. The Dosimetry Centre provides personalised molecular radiotherapy dosimetry, measuring exact radiation distribution and dose delivered to tumours and healthy organs.
• Marsden360 Expert second opinions and personalised cancer treatment recommendations providing patients and clinicians access to specialist multidisciplinary expertise from The Royal Marsden's consultants.
• MyTrack Myeloma Personalised monitoring service for people with myeloma, enabling remote tracking of condition and specialist support to help patients manage their disease.
• Radiotherapy Advanced radiotherapy treatments including CyberKnife stereotactic radiosurgery and intensity-modulated radiotherapy (IMRT), delivered by world-leading specialists for various cancer types.
• Chemotherapy Systematic cancer treatment using pharmaceutical interventions, with personalised planning, administration, and supportive care for patients across all cancer types.
• Surgery Surgical interventions for cancer treatment including planning, anaesthetics, robotic microsurgery using the Symani Surgical System with NanoWrist instruments, and post-operative care.
• Clinical Trials Access to clinical trials for new cancer treatments and therapies across various cancer types, delivered through dedicated research facilities including the NIHR Biomedical Research Centre and the Oak Foundation Drug Development Unit.
• Royal Marsden Private Care Private patient services at Chelsea and Sutton locations for self-paying and insured UK patients, plus international patients, offering rapid access to diagnostics, second opinions, and comprehensive cancer treatment without NHS waiting lists.
• MyMarsden Patient Portal Digital patient portal enabling patients to manage appointments, access medical information, and communicate with healthcare teams.
• The Royal Marsden School Centre of educational excellence offering courses in cancer care and practical training for healthcare professionals, including study days and Return to Practice Nursing programmes.
• NIHR Biomedical Research Centre National Institute for Health and Care Research facility supporting translational biomedical research in cancer, integrated directly with clinical services at the Trust.
• Oak Foundation Drug Development Unit Specialist unit for early-phase cancer drug development and clinical trials, supporting novel therapy research.
• Ralph Lauren Centre for Breast Cancer Research Dedicated breast cancer research centre focusing on innovative treatments and translational research, supporting the Trust's large breast unit which handles around 9,000 new referrals per year.

Quantifiable outcome

• Over 60,000 patients treated per year; treats more private patients than any other cancer centre in the UK
• +1 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Medical Microinstruments (MMI)coreTechnology or IntegrationThe Royal Marsden NHS Foundation Trust performed the first-ever clinical use of MMI's NanoWrist dissection instruments and Synaptix Digital Surgery Platform for the Symani Surgical System. The NanoWrist instruments are the world's first fully wristed robotic tools for dissection in open microsurgery, and Synaptix is the first digital platform built for open microsurgery. This milestone was part of a limited European launch ahead of full commercial availability, with MMI planning global expansion pending regulatory approvals.
• CelLBxHealth PLCminorStrategic or Co-development PartnerCelLBxHealth PLC, a biotech company focused on contract studies for pharmaceutical and diagnostic companies, signed contracted studies with Royal Marsden NHS Foundation Trust as part of its partnership-focused commercial strategy. CelLBxHealth completed a major restructuring in 2025 and signed a master service agreement with AstraZeneca in May 2026.
• Kingston HospitalminorStrategic or Co-development PartnerRoyal Marsden operates a Medical Day Care Unit in partnership with Kingston Hospital, providing day care services for Royal Marsden patients at Kingston Hospital's site.
• Royal Marsden Cancer CharitycoreGTM or Marketing PartnerThe Royal Marsden Cancer Charity raises money solely to support The Royal Marsden NHS Foundation Trust. The charity funds state-of-the-art equipment, groundbreaking research, and the best patient environments. With public support, the charity enables nurses, doctors, and research teams to provide the very best care and develop life-saving treatments used in the UK and globally.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Cleveland Clinic: Global multi-specialty hospital system with a substantial oncology service line; comparable in international patient programme, complex care, and academic research output.
• Mayo Clinic: Large US multi-specialty academic medical centre with a leading cancer programme; broader than The Royal Marsden but comparable in global brand, research intensity, and international patient flow.
• HCA Healthcare UK: Major private hospital operator in the UK including cancer services (e.g., The Wellington, London Bridge); comparable in private UK cancer patient delivery, albeit across a broader multi-specialty portfolio.

Direct peers

• MD Anderson Cancer Center: World-leading US dedicated cancer centre operating as a comprehensive specialty hospital and research institution; directly comparable to The Royal Marsden in mission (cancer-only inpatient/outpatient care, research, education) and global brand positioning.
• Memorial Sloan Kettering Cancer Center: US specialty cancer hospital and research centre; peer in scale of clinical research output, private/academic hybrid model, and global standing as a destination cancer centre.
• The Christie NHS Foundation Trust: The UK's largest single-site cancer centre and fellow NHS specialist cancer trust; closest UK peer in terms of specialist inpatient oncology, private patient unit, and research portfolio.
• Institut Gustave Roussy: Europe's leading comprehensive cancer centre in France; comparable as a large-scale European specialty oncology hospital combining research, clinical trials, and complex cancer treatment.
• Dana-Farber Cancer Institute: US cancer specialty hospital affiliated with Harvard; peer in research-driven oncology care, early-phase trials, and international patient demand.

Regional players

• Charité – Universitätsmedizin Berlin: Europe's largest university hospital with a major oncology programme; comparable in scale, research intensity, and integration of teaching, research, and complex cancer care.

Emerging players

• GenesisCare: Global private oncology provider focused on radiotherapy and chemotherapy; comparable in cancer treatment modalities (radiotherapy, theranostics) but distributed community model versus Royal Marsden's centralised specialist-hospital model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/royalmarsden
• LinkedInlinkedin.com/company/the-royal-marsden-nhs-foundation-trust
• Instagraminstagram.com/royalmarsdennhs
• Xx.com/royalmarsden

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Royal Marsden Hospital